Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement the hemostatic system: an intimate relationship.

Ilene Ceil Weitz1

  • 1Associate Clinical Professor of Medicine, Jane Anne Nohl Division of Hematology, Keck- USC School of Medicine, Los Angeles, CA , United States.

Thrombosis Research
|May 28, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP.

British journal of haematology·2023
Same author

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.

Journal of blood medicine·2023
Same author

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.

American journal of hematology·2021
Same author

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.

Annals of hematology·2021
Same author

Thrombotic Microangiopathy in Cancer.

Seminars in thrombosis and hemostasis·2019
Same author

Complement-mediated thrombotic microangiopathy associated with lupus nephritis.

Blood advances·2018
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

The complement system, crucial for innate immunity, interacts with hemostasis. Its dysregulation causes thrombophilia in conditions like PNH, aHUS, and APLS, with C5b-9 deposition in cancers, offering insights into thrombosis mechanisms.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • The complement system is a key component of innate immunity, closely interacting with the hemostatic system.
  • Dysregulation of complement activation, leading to excessive complement generation, is linked to thrombophilia.
  • Terminal Complement (C5b-9) deposition is observed on endothelial and tumor cells in various cancers.

Purpose of the Study:

  • To explore the intricate relationship between complement system dysregulation and thrombophilia.
  • To investigate the role of Terminal Complement (C5b-9) deposition in cancer.
  • To leverage recent advancements in complement inhibition for understanding thrombosis mechanisms.

Main Methods:

  • Review of existing literature on complement system disorders and thrombosis.
Keywords:
CancerComplementPNHTMAThrombosis

Related Experiment Videos

  • Analysis of studies investigating C5b-9 deposition in Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic uremic Syndrome (aHUS), and antiphospholipid syndrome (APLS).
  • Examination of research on complement inhibition therapies and their impact on thrombotic mechanisms.

    • Main Results:

    • Complement dysregulation, as seen in PNH, aHUS, and APLS, is strongly associated with significant thrombophilia.
    • Terminal Complement (C5b-9) deposition on cell membranes is a common finding in various cancers.
    • Emerging complement inhibition strategies are providing novel insights into the mechanisms driving thrombosis in these conditions.

    Conclusions:

    • The complement system plays a critical role in the pathogenesis of thrombotic disorders.
    • Targeting complement activation presents a potential therapeutic strategy for managing thrombophilia associated with PNH, aHUS, APLS, and cancer.
    • Further research into complement inhibition is essential for a comprehensive understanding of thrombosis in these diseases.